Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma

被引:1
作者
Yulek, Ozden [1 ]
Batur, Sebnem [2 ]
Ozcan, Kerem [3 ]
Yol, Cansu [4 ]
Ulgen, Ovgu Aydin [2 ]
机构
[1] Siirt Res & Training Hosp, Dept Pathol, Siirt, Turkey
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Pathol, Istanbul, Turkey
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA
[4] Univ Hlth Sci, Sch Med, Dept Pathol, Mehmet Akif Inan Training & Res Hosp, Sanliurfa, Turkey
关键词
Cutaneous squamous cell carcinoma; basal cell carcinoma; PD-L1; DEATH-LIGAND; 1; NONMELANOMA SKIN CANCERS; XERODERMA-PIGMENTOSUM; NODAL METASTASIS; LUNG-CANCER; MELANOMA; PEMBROLIZUMAB; ASSOCIATION; SURVIVAL; ANTIBODY;
D O I
10.17305/bjbms.2022.7574
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) and its relationship with prognostic factors in tumors that are not in the head and neck region and are therefore relatively less exposed to the sun. This retrospective cross-sectional study included 25 invasive cSCC and 42 BCC cases with a diameter >= 2 cm located outside the head and neck region from 2010 to 2018. The biopsy samples were examined based on the membranous PD-L1 (22C3 clone) staining. Staining results were scored as follows: 0, no staining (negative); 1, <10% PD-L1 positivity of tumor cells; and 2, >= 10% PD-L1 positivity of tumor cells. PD-L1 positivity was not seen in any BCC cases, whereas 11 (44%) of cSCC cases were PD-L1 positive. No significant relationship was observed between PD-L1 expression and prognostic parameters, including tumor diameter, tumor depth, and lymphovascular or perineural invasion in the cSCC group. PD-L1 expression was not associated with prognostic factors in the early stages of BCC and SCC located outside the head and neck region. Therefore, investigating the PD-L1 expression seems to be more relevant in patients with advanced-stage disease.
引用
收藏
页码:894 / 900
页数:7
相关论文
共 70 条
  • [1] Amin MB, 2017, AJCC CANC STAGING MA, DOI DOI 10.1007/978-3-319-40618-3
  • [2] PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma
    Amoils, Misha
    Kim, Jinah
    Lee, Carolyn
    Sunwoo, John B.
    Colevas, A. Dimitrios
    Aasi, Sumaira Z.
    Hollmig, S. Tyler
    Ma, Yifei
    Divi, Vasu
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2019, 160 (01) : 93 - 99
  • [3] Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead
    Aru, Basak
    Soltani, Mojdeh
    Pehlivanoglu, Cemil
    Guerlue, Ege
    Ganjalikhani-Hakemi, Mazdak
    Yanikkaya Demirel, Guelderen
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Expression of Programmed Death Receptor Ligand 1 with High Tumor Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
    Bae, Sang Byung
    Cho, Hyun Deuk
    Oh, Mee-Hye
    Lee, Ji-Hye
    Jang, Si-Hyong
    Hong, Soon Auck
    Cho, Junhun
    Kim, Sung Yong
    Han, Sun Wook
    Lee, Jong Eun
    Kim, Han Jo
    Lee, Hyun Ju
    [J]. JOURNAL OF BREAST CANCER, 2016, 19 (03) : 242 - 251
  • [5] Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
    Calles, Antonio
    Liao, Xiaoyun
    Sholl, Lynette M.
    Rodig, Scott J.
    Freeman, Gordon J.
    Butaney, Mohit
    Lydon, Christine
    Dahlberg, Suzanne E.
    Hodi, F. Stephen
    Oxnard, Geoffrey R.
    Jackman, David M.
    Jaenne, Pasi A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1726 - 1735
  • [6] Cannon John G D, 2018, JAAD Case Rep, V4, P248, DOI 10.1016/j.jdcr.2018.01.015
  • [7] A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor
    Chang, Anne Lynn S.
    Kim, Jinah
    Luciano, Richard
    Sullivan-Chang, Loretta
    Colevas, Alexander D.
    [J]. JAMA DERMATOLOGY, 2016, 152 (01) : 106 - 108
  • [8] Chang Anne Lynn S., BIOACTIVE CARBOHYDRA, V152, P106, DOI [10.1001/jamadermatol.2015.2705, DOI 10.1016/J.BCDF.2015.11.001, 10.1016/j.preteyeres.2015.08.001, DOI 10.1016/J.PRECAMRES.2015.10.005]
  • [9] Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities
    Chang, Julia
    Zhu, Gefei A.
    Cheung, Christine
    Li, Shufeng
    Kim, Jinah
    Chang, Anne Lynn S.
    [J]. JAMA DERMATOLOGY, 2017, 153 (04) : 285 - 290
  • [10] Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
    Davis, Christina M.
    Lewis, Karl D.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 13